A new class of drug developed at Northwestern University Feinberg School of Medicine shows early promise of being a one-size-fits-all therapy for Alzheimer's disease, Parkinson's disease, multiple sclerosis and traumatic brain injury by reducing inflammation in the brain.
MW151 and MW189 work by preventing the damaging overproduction of proinflammatory cytokines.
Read more at: http://medicalxpress.com/news/2012-07-drug-alzheimer-multiple-sclerosis-brain.html#jCp
No comments:
Post a Comment